327. Examining first dollar coverage of HPV vaccine for adolescents girls and female adults
Session: Poster Abstract Session: Challenges in Vaccinology and Vaccine Exploration
Friday, October 21, 2011
Room: Poster Hall B1
Background:  There is debate over how big a barrier cost-sharing is to immunization. The Patient Protection and Affordable Care Act eliminates cost-sharing for recommended vaccines. This study estimates changes in immunization rates and spending associated with extending first-dollar coverage to privately insured females for human papillomavirus vaccine (HPV).

Methods:  We used the 2008 National Immunization Survey, 2006 MarketScan private claims data, and 2009 Kaiser Family Foundation/Health Research and Educational Trust Employer Health Benefits Survey to estimate the immunization rates and costs that would result from extending first-dollar coverage to all children with private insurance. 

Results:  Over six million privately insured adolescent girls and over eight million female adults age 19-26 are in the target age group to receive HPV vaccine.  Among those with private insurance, 36.9% of adolescent girls and 15.2% female adults were up-to-date on their HPV vaccines.  However, among these groups, cost sharing was associated with lower immunization rates.  Only 28.9% of adolescent girls who face cost sharing were up-to-date for HPV versus 37.5% with first-dollar coverage and 14.2% of female adults who face cost-sharing were up-to date for HPV versus 15.3% with first-dollar coverage. We estimate that eliminating the financial barrier to this vaccine would increase immunization rates modestly by approximately 40,000 adolescent girls and 6,000 female adults. This change results in additional direct spending of $6.5 million to insurers/employers.  Further, these payers would have an additional $5.4 million in spending associated with eliminating cost-sharing for those female adolescents and adults already receiving immunizations.

Conclusion: These findings suggest other strategies should be considered to further increase immunization rates.


Subject Category: I. Adult and Pediatric Vaccines

Angela Shen, MPH, National Vaccine Program Office, US Department of Health and Human Services, Washington, DC and Emily Shortridge, PhD, MPH, MPP, NORC at the University of Chicago, Bethesda, MD

Disclosures:

A. Shen, None

E. Shortridge, None

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.